The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma

Mehdi Taghipour, Charles Marcus, Shani Jones, Rutuparna Sarangi, Tyler J. Trahan, Rathan M. Subramaniam

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To evaluate the impact of fourth and subsequent follow-up PET/computed tomography (PET/CT) scans in patients with non-Hodgkins lymphoma (NHL). MATERIALS AND METHODS: This retrospective study evaluated all biopsy-proven NHL patients who had more than three follow-up scans after completion of primary treatment from 2000 to 2013 at our academic center. Among 586 patients with NHL who had at least one fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT scan at our institution, a total of 77 patients with 208 fourth and subsequent follow-up F-FDG PET/CT scans, were included in the study. The impact of these follow-up scans on the clinical assessment and the management of the patients was evaluated. RESULTS: Among 208 fourth and subsequent follow-up scans, 33 were performed with a previous clinical suspicion of recurrence and 175 were performed without a previous clinical suspicion of recurrence. Fourth and subsequent follow-up PET/CT results were useful in excluding tumor in 27.3% of scan times when there was a clinical suspicion of recurrence and in identifying recurrence in 5.1% of scan times when there was no previous clinical suspicion of recurrence. Clinicians changed management after 36.4% (12/33) scans that were performed with previous clinical suspicion of recurrence and 9.2% (16/175) scans that were performed without previous clinical suspicion (P=0.001). CONCLUSION: Fourth and subsequent follow-up PET/CT scans affect the treatment and management of patients with NHL and add value to clinical assessment and management, especially in patients with a previous clinical suspicion of recurrence.

Original languageEnglish (US)
JournalNuclear Medicine Communications
DOIs
StateAccepted/In press - Mar 17 2016

Fingerprint

Fluorodeoxyglucose F18
Non-Hodgkin's Lymphoma
Tomography
Recurrence
Therapeutics
Retrospective Studies
Biopsy
Neoplasms

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma. / Taghipour, Mehdi; Marcus, Charles; Jones, Shani; Sarangi, Rutuparna; Trahan, Tyler J.; Subramaniam, Rathan M.

In: Nuclear Medicine Communications, 17.03.2016.

Research output: Contribution to journalArticle

Taghipour, Mehdi ; Marcus, Charles ; Jones, Shani ; Sarangi, Rutuparna ; Trahan, Tyler J. ; Subramaniam, Rathan M. / The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma. In: Nuclear Medicine Communications. 2016.
@article{4e9107df90cc4e81a130fbe07d5df496,
title = "The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma",
abstract = "OBJECTIVE: To evaluate the impact of fourth and subsequent follow-up PET/computed tomography (PET/CT) scans in patients with non-Hodgkins lymphoma (NHL). MATERIALS AND METHODS: This retrospective study evaluated all biopsy-proven NHL patients who had more than three follow-up scans after completion of primary treatment from 2000 to 2013 at our academic center. Among 586 patients with NHL who had at least one fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT scan at our institution, a total of 77 patients with 208 fourth and subsequent follow-up F-FDG PET/CT scans, were included in the study. The impact of these follow-up scans on the clinical assessment and the management of the patients was evaluated. RESULTS: Among 208 fourth and subsequent follow-up scans, 33 were performed with a previous clinical suspicion of recurrence and 175 were performed without a previous clinical suspicion of recurrence. Fourth and subsequent follow-up PET/CT results were useful in excluding tumor in 27.3{\%} of scan times when there was a clinical suspicion of recurrence and in identifying recurrence in 5.1{\%} of scan times when there was no previous clinical suspicion of recurrence. Clinicians changed management after 36.4{\%} (12/33) scans that were performed with previous clinical suspicion of recurrence and 9.2{\%} (16/175) scans that were performed without previous clinical suspicion (P=0.001). CONCLUSION: Fourth and subsequent follow-up PET/CT scans affect the treatment and management of patients with NHL and add value to clinical assessment and management, especially in patients with a previous clinical suspicion of recurrence.",
author = "Mehdi Taghipour and Charles Marcus and Shani Jones and Rutuparna Sarangi and Trahan, {Tyler J.} and Subramaniam, {Rathan M.}",
year = "2016",
month = "3",
day = "17",
doi = "10.1097/MNM.0000000000000504",
language = "English (US)",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - The value of fourth and subsequent post-treatment 18F-FDG PET/CT scans in the management of patients with non-Hodgkin’s lymphoma

AU - Taghipour, Mehdi

AU - Marcus, Charles

AU - Jones, Shani

AU - Sarangi, Rutuparna

AU - Trahan, Tyler J.

AU - Subramaniam, Rathan M.

PY - 2016/3/17

Y1 - 2016/3/17

N2 - OBJECTIVE: To evaluate the impact of fourth and subsequent follow-up PET/computed tomography (PET/CT) scans in patients with non-Hodgkins lymphoma (NHL). MATERIALS AND METHODS: This retrospective study evaluated all biopsy-proven NHL patients who had more than three follow-up scans after completion of primary treatment from 2000 to 2013 at our academic center. Among 586 patients with NHL who had at least one fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT scan at our institution, a total of 77 patients with 208 fourth and subsequent follow-up F-FDG PET/CT scans, were included in the study. The impact of these follow-up scans on the clinical assessment and the management of the patients was evaluated. RESULTS: Among 208 fourth and subsequent follow-up scans, 33 were performed with a previous clinical suspicion of recurrence and 175 were performed without a previous clinical suspicion of recurrence. Fourth and subsequent follow-up PET/CT results were useful in excluding tumor in 27.3% of scan times when there was a clinical suspicion of recurrence and in identifying recurrence in 5.1% of scan times when there was no previous clinical suspicion of recurrence. Clinicians changed management after 36.4% (12/33) scans that were performed with previous clinical suspicion of recurrence and 9.2% (16/175) scans that were performed without previous clinical suspicion (P=0.001). CONCLUSION: Fourth and subsequent follow-up PET/CT scans affect the treatment and management of patients with NHL and add value to clinical assessment and management, especially in patients with a previous clinical suspicion of recurrence.

AB - OBJECTIVE: To evaluate the impact of fourth and subsequent follow-up PET/computed tomography (PET/CT) scans in patients with non-Hodgkins lymphoma (NHL). MATERIALS AND METHODS: This retrospective study evaluated all biopsy-proven NHL patients who had more than three follow-up scans after completion of primary treatment from 2000 to 2013 at our academic center. Among 586 patients with NHL who had at least one fluorine-18 fluorodeoxyglucose (F-FDG) PET/CT scan at our institution, a total of 77 patients with 208 fourth and subsequent follow-up F-FDG PET/CT scans, were included in the study. The impact of these follow-up scans on the clinical assessment and the management of the patients was evaluated. RESULTS: Among 208 fourth and subsequent follow-up scans, 33 were performed with a previous clinical suspicion of recurrence and 175 were performed without a previous clinical suspicion of recurrence. Fourth and subsequent follow-up PET/CT results were useful in excluding tumor in 27.3% of scan times when there was a clinical suspicion of recurrence and in identifying recurrence in 5.1% of scan times when there was no previous clinical suspicion of recurrence. Clinicians changed management after 36.4% (12/33) scans that were performed with previous clinical suspicion of recurrence and 9.2% (16/175) scans that were performed without previous clinical suspicion (P=0.001). CONCLUSION: Fourth and subsequent follow-up PET/CT scans affect the treatment and management of patients with NHL and add value to clinical assessment and management, especially in patients with a previous clinical suspicion of recurrence.

UR - http://www.scopus.com/inward/record.url?scp=84961231199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961231199&partnerID=8YFLogxK

U2 - 10.1097/MNM.0000000000000504

DO - 10.1097/MNM.0000000000000504

M3 - Article

C2 - 26990623

AN - SCOPUS:84961231199

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

ER -